Barclays Lowers Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $4.00
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its price objective cut by analysts at Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target indicates a potential upside of 123.46% from the […]
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its price objective cut by analysts at Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target indicates a potential upside of 123.46% from the […]
